Autologous self-tolerance inducing cells of monocytic origin and their use in pharmaceutical preparations
OwnerBernd Karl Friedrich Kremer, Fred Fandrich +1inventors
InventorsBernd Karl Friedrich Kremer, Fred Fandrich, Maren Schulze
Life of this patent
Estimating the term…
Abstract
The invention relates to cells of monocytic origin suitable for the prevention and/or treatment of diseases associated with disturbed self-tolerance, in particular autoimmune diseases and allergies, and to pharmaceutical preparations containing these cells. The cells are autologous in relation to the patient to whom they are to be administered. The invention further relates to a process for the generation and/or, propagation of autologous regulatory T cells.
Claims41
1-37. (canceled)
A method of preparing self-tolerance inducing cell of monocytic origin for the prevention, treatment, or prevention and treatment of diseases associated with disturbed self-tolerance in a patient comprising:
- a. isolating a monocyte from the blood of a patient to whom the cells are to be administered;
- b. multiplying said monocyte in vitro in a suitable culture medium comprising macrophage-colony stimulating factor (M-CSF);
- c. cultivating said monocytes simultaneously with or following step b) in a culture medium containing gamma-interferon (γ-IFN);
- and
- d. separating a self-tolerance inducing cell of monocytic origin formed in step c) from said culture medium.
A self-tolerance inducing cell of monocytic origin for the prevention, treatment, or prevention and treatment of diseases associated with disturbed self-tolerance in a patient capable of being obtained by a process comprising:
- a. isolating a monocyte from the blood of a patient to whom the cells are to be administered;
- b. multiplying said monocyte in vitro in a suitable culture medium comprising macrophage-colony stimulating factor (M-CSF);
- c. cultivating said monocytes simultaneously with or following step b) in a culture medium containing gamma-interferon (γ-IFN);
- and
- d. separating a self-tolerance inducing cell of monocytic origin formed in step c) from said culture medium.
A cell preparation comprising a self-tolerance inducing cell of monocytic origin capable of being obtained by a process comprising:
- a. isolating a monocyte from the blood of a patient to whom the cells are to be administered;
- b. multiplying said monocyte in vitro in a suitable culture medium comprising macrophage-colony stimulating factor (M-CSF);
- c. cultivating said monocytes simultaneously with or following step b) in a culture medium containing gamma-interferon (γ-IFN);
- and
- d. separating a self-tolerance inducing cell of monocytic origin formed in step c) from said culture medium;
- and
- e. suspending said self-tolerance inducing cell of monocytic origin in a suitable medium.
A method of preventing, treating, or preventing and treating a disease associated with disturbed self-tolerance in a patient in need thereof comprising administering a pharmaceutically effective amount of a pharmaceutical composition comprising a self-tolerance inducing cell of monocytic origin capable of being obtained by a process comprising:
- a. isolating a monocyte from the blood of a patient to whom the cells are to be administered;
- b. multiplying said monocyte in vitro in a suitable culture medium comprising macrophage-colony stimulating factor (M-CSF);
- c. cultivating said monocytes simultaneously with or following step b) in a culture medium containing gamma-interferon (γ-IFN);
- and
- d. separating a self-tolerance inducing cell of monocytic origin formed in step c) from said culture medium, wherein said self-tolerance inducing cell of monocytic origin co-expresses antigens CD3 and CD14.
A pharmaceutical composition comprising a self-tolerance inducing cell of monocytic origin capable of being obtained by a process comprising:
- a. isolating a monocyte from the blood of a patient to whom the cells are to be administered;
- b. multiplying said monocyte in vitro in a suitable culture medium comprising macrophage-colony stimulating factor (M-CSF);
- c. cultivating said monocytes simultaneously with or following step b) in a culture medium containing gamma-interferon (γ-IFN);
- and
- d. separating a self-tolerance inducing cell of monocytic origin formed in step c) from said culture medium.
A method of manufacturing a pharmaceutical composition for the preventing, treating, or preventing and treating of a disease associated with disturbed self-tolerance comprising:
- a. isolating a monocyte from the blood of a patient to whom the cells are to be administered;
- b. multiplying said monocyte in vitro in a suitable culture medium comprising macrophage-colony stimulating factor (M-CSF);
- c. cultivating said monocytes simultaneously with or following step b) in a culture medium containing gamma-interferon (γ-IFN);
- and
- d. separating a self-tolerance inducing cell of monocytic origin formed in step c) from said culture medium.
A method of manufacturing a pharmaceutical composition for the preventing, treating, or preventing and treating an allergy comprising:
- a. isolating a monocyte from the blood of a patient to whom the cells are to be administered;
- b. multiplying said monocyte in vitro in a suitable culture medium comprising macrophage-colony stimulating factor (M-CSF);
- c. cultivating said monocytes simultaneously with or following step b) in a culture medium containing gamma-interferon (γ-IFN);
- and
- d. separating a self-tolerance inducing cell of monocytic origin formed in step c) from said culture medium.
A method of detecting, selecting, or detecting and selecting a self-tolerance inducing cell of monocytic origin suitable for preventing, treating, or preventing and treating a disease associated with disturbed self-tolerance in a patient in need thereof comprising adding a monoclonal antibody produced by hybridoma GM-7, deposited under DSMZ Accession No. DSM ACC2542.
Dependencies are inferred from the claim text.